EUVIMEDEUVIMED entdecken
Open Access

Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Nazia Rashid, Paul Saenger, Yi-Lin Wu, Heike Woehling, Matthew Frankel, Fima Lifshitz, Michael Muenzberg, Robert Rapaport

Biologics in Therapy · 2014

DOI: 10.1007/s13554-014-0017-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biologics in Therapy, 2014. Verfasst von Nazia Rashid und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente, Southern California Region, Drug Information Services, Downey, CA, USA. Nazia.X.Rashid@kp.org. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study was conducted using an integrated retrospective database to evaluate the effectiveness of Omnitrope(®) (Sandoz) on children with growth hormone deficiency (GHD), idiopathic short stature (ISS), and Turner Syndrome (TS) who switched from a non-Omnitrope recombinant human growth hormone (rhGH) preparation during routine clinical care. METHODS: This was a retrospective study which identified patients with GHD, ISS, and TS during the study time period of January 1, 2006 and July 31, 2011. Patients were included if they switched to Omnitrope from another non-Omnitrope rhGH therapy during the study time period, were

Schlagwörter

Stichwörter der Autor:innen

BiologicsChildrenGrowth hormone deficiency (GHD)Idiopathic short stature Omnitrope®Recombinant human growth hormone (rhGH)SwitchingTurner syndrome

Autor:innen und Institutionen

  • Kaiser Permanente, Southern California Region, Drug Information Services, Downey, CA, USA. Nazia.X.Rashid@kp.org.
  • Department of Pediatrics, Albert Einstein College of Medicine, New York, NY, USA.
  • Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, USA.
  • Sandoz International GmbH, Holzkirchen, Germany.
  • Sandoz Inc., Princeton, NJ, USA.
  • Pediatric Sunshine Academics, Santa Barbara, CA, USA.

Zitieren

APA

Rashid, N., Saenger, P., Wu, Y. L., Woehling, H., Frankel, M., Lifshitz, F., Muenzberg, M., & Rapaport, R. (2014). Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. Biologics in Therapy. https://doi.org/10.1007/s13554-014-0017-1

Vancouver

Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, et al. Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. Biologics in Therapy. 2014. doi:10.1007/s13554-014-0017-1

BibTeX
@article{Rashid2014,
  author = {Rashid, Nazia and Saenger, Paul and Wu, Yi-Lin and Woehling, Heike and Frankel, Matthew and Lifshitz, Fima and Muenzberg, Michael and Rapaport, Robert},
  title = {Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System},
  journal = {Biologics in Therapy},
  year = {2014},
  doi = {10.1007/s13554-014-0017-1}
}
Kostenlos starten →